High urinary glucose is associated with improved renal prognosis in patients with diabetes mellitus

Yuya Itano1,2, Hiroshi Sobajima2, Norimichi Ohashi2, Taiga Shibata2, Atsushi Fujiya2, Takanobu Nagata3, Masahiko Ando4, Takahiro Imaizumi4, Yoko Kubo5, Takaya Ozeki1, Takayuki Katsuno1,6, Sawako Kato1, Yoshinari Yasuda1, Shoichi Maruyama1*

1Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan, 2Department of Diabetology and Nephrology, Ogaki Municipal Hospital, Ogaki, Gifu, Japan, 3Department of Nephrology, Yokkaichi Municipal Hospital, Yokkaichi, Mie, Japan, 4Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Aichi, Japan, 5Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan, and 6Department of Nephrology and Rheumatology, Aichi Medical University, Nagakute, Aichi, Japan

Keywords
Diabetes mellitus, Glycosuria, Renal insufficiency

*Correspondence
Shoichi Maruyama
Tel: +81-52-741-2111
Fax: +81-52-744-2785
E-mail address: marus@med.nagoya-u.ac.jp

J Diabetes Investig 2021; 12: 998–1006
doi: 10.1111/jdi.13428

INTRODUCTION
Chronic kidney disease (CKD) leads to end-stage renal disease. Furthermore, the condition is associated with the onset of cardiovascular disease (CVD)1,2, and the incidence of these three diseases is increasing worldwide. Diabetes mellitus is one of the most important risk factors for renal dysfunction and CVD, and affects health and quality of life through the development of microvascular and macrovascular complications3-5.

A recent study has generated significant new knowledge regarding sodium–glucose cotransporter (SGLT) 2 inhibitors, which has had a huge impact on the current understanding of diabetes6. The therapeutic effects of SGLT2 inhibitors include strong protective effects against CVD and renal function beyond the control of blood glucose levels in patients with type 2 diabetes7. A number of potential pathways have been suggested to underly the renoprotective effects of these inhibitors. Although the precise mechanisms remain unclear, it is expected that increased renal glucose excretion is key to the therapeutic effects of SGLT2 inhibitors8.

Renal glycosuria is defined as the excretion of glucose at abnormally high levels despite blood glucose levels being within the normal range. This occurs when the threshold for glucose
reabsorption in the renal tubules is decreased. In general, renal
glycosuria is thought to be a benign disease for kidney function,
but there is a possibility that it has beneficial effects for various
other organs\(^9\). Specifically, the condition has been reported to
be associated with improved renal outcomes in CKD patients
without diabetes\(^{10}\). Among patients with type 2 diabetes,
improved effects have been reported in patients with renal gly-
cosuria with respect to risk factors for CVD, including body
mass index (BMI) and homeostatic model assessment of insulin
resistance score\(^{11}\).

It is therefore important to reconsider the significance of urin-
ary glucose excretion in patients with diabetes. Urinary glu-
cose excretion increases after the administration of SGLT2
inhibitors; nevertheless, there are few studies on the association
of urinary glucose levels with kidney function in the absence of
SGLT2 inhibitors. The purpose of the present study was to
investigate this association in patients with diabetes who were
not using SGLT2 inhibitors.

METHODS
Study design and participants
The present study was a retrospective, observational cohort
study. Study participants included patients with diabetes who
regularly visited the Department of Diabetology and Nephro-
logy, Ogaki Municipal Hospital, Ogaki, Japan. The hospital is
a regional core and tertiary referral hospital. We recruited all
patients who met the criteria from 1 January 2007 to 31
December 2011, and collected baseline clinical and laboratory
data during this period. The baseline data used for statistical
analysis were the results of the first and single measurement
carried out in the hospital. Follow-up data were collected
until 30 June 2015. We enrolled patients who: (i) were diag-
nosed with type 1 or 2 diabetes at our hospital; (ii) attended
regular appointments (every 1–3 months) at the Department
of Diabetology and Nephrology for at least 1 year; and (iii)
had a baseline estimated glomerular filtration rate (eGFR) of
>30 ml/min \(\times 1.73 m^2\). The following patients were excluded
from the analysis: (i) patients who could not complete a 24-
h urinary collection test or who were judged to have crea-
tinex excretion that deviated by \(\pm 25\%\) of the predicted value
calculated according to age, sex, height and weight\(^{12,13}\); (ii)
patients with missing laboratory data for parameters, such as
urinary albumin or urinary glucose; (iii) patients with miss-
ing follow-up data on kidney function from blood tests at
Ogaki Municipal Hospital after the baseline laboratory tests;
(iv) patients with comorbidities of systemic diseases, such as
autoimmune diseases and vasculitis, primary glomerular dis-
ases, neoplasms or liver cirrhosis, at baseline because of the
possibility that these diseases and their treatments affect dia-
betes control and renal function; and (v) patients in whom
the onset of diabetes was within 5 years, because renal events
within this period are considered atypical in terms of kidney
dysfunction.

The present study and its protocols were approved by the
ethics committee of Ogaki Municipal Hospital (approval num-
ber: 20161222-4) and conformed to the provisions of the Decla-
ration of Helsinki, as revised in Fortaleza, Brazil (October
2013). Having been approved by the ethics committee, we
guaranteed patients the opportunity to opt out. The require-
ment for the acquisition of informed consent from patients was
waived owing to the retrospective nature of the study.

Categorization of patients by quantification of urinary glucose
There are currently no clear criteria for the categorization
of urinary glucose level. Therefore, we designed a system for catego-
rization and analyzed data using the following procedure: (i)
we divided the study cohort using sextiles for the quantification
of urinary glucose; and (ii) based on the result, we subsequently
divided the patients into two groups: those with urinary glucose
>5 g/day and those with urinary glucose <5 g/day.

Clinical outcomes
The primary clinical outcome was a 30% decline in eGFR rela-
tive to baseline. Baseline eGFR was taken as the first measure-
ment of eGFR within the study period. Patients were followed
up until an event occurred or until 30 June 2015. When dis-
ases that were regarded as exclusion criteria developed during
follow up, patients were considered a censored case at the time
of diagnosis. We calculated eGFR using the following equa-
tion of the Japanese Society of Nephrology: eGFR \(\text{mL/min}
\times 1.73 m^2\) = 194 \times serum creatinine\(^{1.094}\) \times age\(^{-0.287}\) (for men)
or 194 \times serum creatinine\(^{1.094}\) \times age\(^{-0.287}\) \times 0.739 (for
women)\(^{14}\).

Procedure
A diagnosis of type 1 or 2 diabetes was established by a specialist
at the Department of Diabetology. Systolic and diastolic blood
pressure measurements were carried out in the hospital, and
hypertension was defined as systolic blood pressure \(\geq 140\)
mmHg, diastolic blood pressure \(\geq 90\) mmHg or the use of antihyperten-
sive medication. Albuminuria and urinary glucose were measured
using a 24-h urine-collection test, and urine volume was self-re-
ported. Use of oral hypoglycemic agents was recorded, defined as
all types of medication excluding SGLT2 inhibitors (e.g., biguan-
ide, \(\alpha\)-glucosidase inhibitors, thiazolidine derivatives, sulfony-
lurea, dipeptidyl peptidase four inhibitors, glinide). Use of renin–
angiotensin–aldosterone system blockers were also recorded,
including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and direct renin inhibitors.

For interaction analysis, we categorized some variables into
two subgroups. Age was categorized as either \(\geq 65\) or \(< 65\) years,
total cholesterol as \(\geq 220\) or \(< 220\) mg/dL, duration of diabetes
as \(\geq 10\) or \(< 10\) years, eGFR as \(\geq 76.7\) or \(< 76.7\) ml/min
\(\times 1.73 m^2\), albuminuria as \(\geq 30\) mg/day or \(< 30\) mg/day, BMI as
\(\geq 25\) or \(< 25\) kg/m\(^2\) and glycated hemoglobin (HbA1c) level as
either \(\geq 7\%\) or \(< 7\%\).
Statistical analysis

All statistical analyses were carried out using Stata version 15.0 (StataCorp LLC, College Station, TX, USA). Urinary glucose level, age, duration of diabetes, existence of hypertension, eGFR, total cholesterol, albuminuria, sex, BMI and HbA1c level were used as independent variables for adjustment. There were no missing data. Data are expressed as the number and percentage for categorical variables or as the median/interquartile range for continuous variables. Between-group differences in baseline characteristics were evaluated using unpaired Student’s t-test for continuous variables, and the unpaired χ²-test for categorical variables. First, we analyzed the association between 24-h urinary glucose excretion and kidney function. The groups of 24-h urinary glucose excretion were categorized using sextiles, and we analyzed the primary outcome using the Cox proportional hazards model. Second, we carried out the same analysis of urinary glucose excretion after dividing the data into two groups using the threshold of 5 g/day for glucose excretion based on the result of the first analysis. Third, we used the Cox proportional hazards model including the interaction terms between high glycosuria (≥5 g/day) and other variables. Finally, we used multivariable fractional polynomial interaction approach to determine the effects of higher urinary glucose on the renal outcome in patients with different levels of HbA1c. Statistical significance was accepted at P < 0.05.

RESULTS

Study population

In total, 4,184 patients were recruited for this study. After the application of inclusion and exclusion criteria, 1,172 patients were finally enrolled (Figure 1). Baseline characteristics of all participants are summarized in Table 1. Patients were divided into six preliminary groups according to urinary glucose levels, and Cox regression analysis was carried out. There was a clearly large difference in the hazard ratio (HR) between the top two sextiles with urinary glucose ≥5.135 g/day and the other four sextiles with urinary glucose <5.135 g/day (Figure 2). The change in HR was not linear, and it seemed that the threshold for urinary glucose excretion was approximately 5 g/day. Therefore, we deemed that it would not be appropriate to determine the effect of urinary glucose on continuous variables, and decided to evaluate the categorical variables by dividing the patients into two groups using a urinary glucose excretion level of 5 g/day. We divided the patients into two groups, because the dividing point approximated 5 g/day. Patients in the ≥5 g/day urinary glucose group were younger; had higher body-weight, higher BMI and higher eGFR; and were more likely to be men and diagnosed with type 2 diabetes than those in the <5 g/day urinary glucose group. The prevalence of diabetic retinopathy, higher HbA1c levels, high blood glucose levels, the rate of insulin use and the proportion of type 1 diabetes were higher in the high urinary glucose group, indicating poor glycemic control in this group (Table 1).

Follow-up time and outcome data

The median follow-up duration was 6.6 years (interquartile range 3.7–7.3 years). There were no missing data for any variable of interest, and renal events occurred in 121 patients.

Cox regression analysis for the renal outcome of 30% decline in eGFR from baseline

In the univariate model, no significant associations between urinary glucose excretion and renal outcome were observed. Multivariate analysis using the baseline variables of age, BMI, duration of diabetes, presence of hypertension, eGFR, total cholesterol, albuminuria, urinary glucose, sex and HbA1c level showed that higher age (adjusted HR 1.04, 95% confidence interval [CI] 1.01–1.06; P = 0.002), higher albuminuria (adjusted HR 2.82, 95% CI 2.09–3.81; P < 0.001), urinary glucose of ≥5 g/day (adjusted HR 0.58, 95% CI 0.35–0.96; P = 0.034) and higher HbA1c level (adjusted HR 1.02, 95% CI 1.00–1.04; P = 0.031) were significantly associated with reduced risk of renal event (Table 2). When factored into the models, the type of diabetes was not a significant factor, and the point estimates of urinary glucose, the main exposure of interest, showed similar results (data not shown).

Analysis using interaction terms

Cox regression analysis including the interaction terms between high urinary glucose excretion and other renal outcome variables showed a significant interaction between high urinary glucose and male sex (adjusted HR 0.32, 95% CI 0.16–0.66; P = 0.006), low BMI (adjusted HR 0.36, 95% CI 0.17–0.77; P = 0.034) and duration of diabetes ≥10 years (adjusted HR 0.34, 95% CI 0.17–0.69; P < 0.001; Figure 3). Interactions with other factors were not significant.

Multivariate Cox regression analysis, including the interaction terms between high urinary glucose excretion and all three aforementioned factors, showed significant interactions with male sex (adjusted HR 0.33, 95% CI 0.14–0.74; P = 0.007) and duration of diabetes ≥10 years (adjusted HR 0.25, 95% CI 0.11–0.58; P = 0.001). No interaction was detected with BMI (adjusted HR 0.52, 95% CI 0.23–1.19; P = 0.126; Table 3).

Multivariable fractional polynomial interaction approach

The multivariable functional polynomial interaction plots represent the interaction among linear and non-linear variables. In the present study, we examined the association of the interaction between HbA1c and the main exposure (urinary glucose <5 or ≥5 g/day) with the outcome. Therefore, the HRs of the main exposure can be illustrated across levels of HbA1c (Figure 4).

DISCUSSION

In the present retrospective observational study, we observed that in addition to higher age, albuminuria, HbA1c and urinary glucose levels of ≥5 g/day (defined as high urinary glucose)
Table 1 | Baseline characteristics of participants categorized into two groups using urinary glucose level of 5 g/day as the cut-off point

| Variable                      | All          | Glucose <5 g | Glucose ≥5 g | P-value |
|-------------------------------|--------------|--------------|--------------|---------|
| n                             | 1,172        | 775          | 397          |         |
| Age (years)                   | 64 (57–70)   | 65 (58–71)   | 61 (53–68)   | <0.001* |
| Height (cm)                   | 159 (152–166)| 157 (151–164)| 162 (155–168)| <0.001* |
| Weight (kg)                   | 60 (53–68)   | 59 (52–67)   | 63 (55–71)   | <0.001* |
| BMI (kg/m²)                   | 23.9 (21.7–26.5) | 23.8 (21.5–26.3) | 24.2 (21.9–26.8) | 0.035* |
| Duration of diabetes (years)  | 10.6 (6.2–17.1)| 10.4 (5.8–17.1)| 11.2 (6.9–17.0) | 0.273  |
| Systolic blood pressure (mmHg)| 131 (120.0–143.5)| 131 (120–140) | 130 (119–142) | 0.350  |
| Diastolic blood pressure (mmHg)| 72 (64–80)   | 71 (64–79)   | 74 (66–82)   | <0.001* |
| Creatinine (mg/mL)            | 0.7 (0.59–0.83)| 0.7 (0.59–0.85)| 0.7 (0.58–0.81)| 0.003* |
| eGFR, mL/min (1.73 m²)        | 76.7 (65.9–89.9)| 74.1 (63.0–85.9)| 82.4 (71.2–97.5)| <0.001* |
| HbA1c (mmol/L)                | 54 (49–62)   | 52 (46–57)   | 63 (66–68)   | <0.001* |
| HbA1c (%)                     | 71 (6.6–7.8) | 69 (6.4–7.4) | 79 (7.3–8.4) | <0.001* |
| Total cholesterol (mg/dL)     | 198 (175–220)| 197 (175–221)| 200 (176–219)| 0.631  |
| Triglycerides (mg/dL)         | 99 (72–143.5)| 99 (71–136)  | 99 (73–156)  | 0.001* |
| HDL cholesterol (mg/dL)       | 51 (43–62)   | 51 (43–60)   | 51 (43–63)   | 0.090  |
| LDL cholesterol (mg/dL)       | 120 (100.5–140)| 121 (101–142)| 117 (99–138) | 0.098  |
| Albuminuria (mg/day)          | 12.3 (6.5–30.4)| 11.5 (6.3–27.8)| 15.2 (6.9–35.3)| 0.468  |
| Urine volume (L/day)          | 1.6 (1.4–2.1) | 1.6 (1.3–2.0)| 1.7 (1.5–2.1)| <0.001* |
| Glycosuria (g/day)            | 1.98 (0.30–8.66)| 0.58 (0.12–1.92)| 14.4 (8.55–25.82)| <0.001* |
| Male sex                      | 617 (52.65)  | 355 (45.81)  | 262 (65.99)  | <0.001* |

Continuous data are presented as the median (25th–75th percentile), whereas categorical data are presented as absolute numbers (%). Between-group differences in baseline characteristics were evaluated using unpaired Student’s t-test for continuous variables, and unpaired χ²-test for categorical variables. BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein. *Values with P < 0.05 were considered to be statistically significant.
were significantly associated with the occurrence of a 30% decline in eGFR relative to the baseline.

Analysis of the association between renal events, as indicated by a <30% decline in eGFR, and baseline variables including interaction terms showed that high urinary glucose levels exhibited better renal outcomes, especially in male patients or those with duration of diabetes ≥10 years.

To the best of our knowledge, this is the first study to investigate the clinical significance of urinary glucose levels in terms of kidney function among patients with diabetes who are not using SGLT2 inhibitors.

In patients with diabetes, glycosuria generally develops when urinary glucose concentration exceeds the renal tubular reabsorption capacity (which is ~10 mmol/L). Increased glycosuria is commonly an indicator of poor glycemic control; however, the threshold differs between individuals, and has been reported to be higher in women and older patients. Glycosuria can also occur in individuals without diabetes. This is referred to as renal glycosuria, a condition in which urinary glucose excretion occurs even when blood glucose levels are within the normal range. This is an effect of compromised renal tubule function and has been suggested to be induced by genetic mutation or variation. For these reasons, the level of glycosuria can indicate glycemic control, as well as renal tubule impairment.

A recent report showed beneficial effects of SGLT2 inhibitors on all-cause mortality, CVD and kidney function in patients with type 2 diabetes. Several mechanisms of the renoprotective effects of these drugs have been proposed, including enhanced sodium excretion, increased efficiency of energy utilization in tubular cells and ketone production. It was not until recently, however, that researchers started to show interest in glycosuria. Hung et al. reported that the presence of glycosuria or renal glycosuria is associated with favorable renal outcomes in stage 5 CKD patients without diabetes. Although this suggests the beneficial effects of glycosuria, the authors did not investigate the effects of glycosuria in patients with diabetes. Gong et al. showed that, among patients with type 2 diabetes, glycosuria is independently associated with a lower risk of CVD, as indicated by features that include lower homeostatic model assessment of insulin resistance, lower BMI, lower blood

Table 2 | Association of baseline variables with 30% decline in estimated glomerular filtration rate from baseline

| Variable                      | Univariate HR (95% CI) | P value | Multivariate HR (95% CI) | P-value |
|-------------------------------|------------------------|---------|--------------------------|---------|
| Age (years)                   | 1.05 (1.02–1.07)       | <0.001  | 1.04 (1.01–1.06)         | 0.002*  |
| BMI (kg/m²)                   | 1.06 (1.01–1.11)       | 0.013   | 1.04 (0.99–1.10)         | 0.111   |
| Duration of diabetes (years)  | 1.03 (1.01–1.05)       | 0.006   | 1.01 (0.98–1.03)         | 0.539   |
| Hypertension                  | 2.28 (1.48–3.52)       | <0.001  | 1.24 (0.78–1.98)         | 0.354   |
| Baseline eGFR, mL/min (1.73 m²) | 0.98 (0.98–0.99)     | 0.010   | 1.01 (0.99–1.02)         | 0.374   |
| Total cholesterol (10 mg/dL)  | 1.01 (0.96–1.07)       | 0.592   | 1.03 (0.98–1.08)         | 0.294   |
| Albuminuria (mg/day)          | 3.09 (2.33–4.10)       | <0.001  | 2.82 (2.09–3.81)         | <0.001* |
| Urinary glucose level ≥5 g/day| 0.75 (0.50–1.11)       | 0.156   | 0.58 (0.35–0.96)         | 0.034*  |
| Female sex                    | 1.41 (0.99–2.04)       | 0.056   | 1.15 (0.78–1.73)         | 0.471   |
| HbA1c (%)                     | 1.02 (0.99–1.03)       | 0.051   | 1.02 (1.00–1.04)         | 0.031*  |

The univariate and multivariate Cox proportional hazards models were carried out after adjustment for baseline variables of age, body mass index (BMI), duration of diabetes, presence of hypertension, estimated glomerular filtration rate (eGFR), total cholesterol, albuminuria, urinary glucose level, sex and glycated hemoglobin (HbA1c) level. CI, confidence interval; HR, hazard ratio. *Values with P < 0.05 were considered to be statistically significant.
pressure and lower fasting blood glucose. Their study showed the beneficial effects of glycosuria in patients with diabetes; nevertheless, it was a cross-sectional study that did not analyze kidney function.

In the present study, patients were divided into sextiles, and multivariate Cox hazards analysis was carried out. We found that patients in the top two sextiles with urinary glucose ≥5.135 g/day showed a lower risk of eGFR decline than those in the other four sextiles. We subsequently divided patients into two groups using the threshold of 5 g/day for urinary glucose, and performed a longitudinal analysis. The result showed that, among patients with similar blood glucose control who were not using SGLT2 inhibitors, urinary glucose excretion of >5 g/day was significantly associated with better kidney function compared with that of <5 g/day. Together with the results of previous studies, this suggests that excretion of high urinary glucose levels leads to better prognosis for kidney function. Several hypotheses have been suggested to explain the mechanism of this effect. First, individuals with high urinary glucose levels will experience benefits similar to those observed in individuals...
using SGLT2 inhibitors, and might show higher sodium excretion and suppressed glomerular hyperfiltration due to tubuloglomerular feedback. Furthermore, high urinary glucose might limit oxygen consumption in the tubules, leading to improved oxygenation in the kidneys. Animal studies have shown that genetic knockout of SGLT2 leads to a reduction in

### Table 3 | Association between baseline variables, including interaction terms between higher urinary glucose levels and body mass index <25, male sex, and duration of diabetes ≥10 years, with 30% decline in estimated glomerular filtration rate from baseline

| Variable                                      | HR (95% CI)       | P-value |
|------------------------------------------------|-------------------|---------|
| Age (years)                                    | 1.04 (1.02–1.07)  | <0.001* |
| Hypertension                                   | 1.31 (0.82–2.10)  | 0.243   |
| Baseline eGFR, mL/min (1.73 m²)                | 1.00 (0.99–1.01)  | 0.443   |
| Total cholesterol (10 mg/dL)                   | 1.00 (0.99–1.01)  | 0.279   |
| Albuminuria (mg/day)                           | 3.00 (2.21–4.07)  | <0.001* |
| Urinary glucose level ≥5 g/day                 | 3.28 (1.44–7.45)  | 0.005*  |
| Male (sex)                                     | 1.18 (0.75–1.86)  | 0.451   |
| Interaction term between urinary glucose level ≥5 g/day and male sex | 0.33 (0.14–0.74) | 0.007*  |
| BMI <25 kg/m²                                  | 0.84 (0.55–1.31)  | 0.454   |
| Interaction term between urinary glucose level ≥5 g/day and BMI <25 kg/m² | 0.52 (0.23–1.19) | 0.126   |
| Duration of diabetes ≥10 years                 | 1.47 (0.90–2.37)  | 0.116   |
| Interaction term between urinary glucose level ≥5 g/day and duration of diabetes ≥10 years | 0.25 (0.11–0.58) | 0.001*  |
| HbA1c (%)                                      | 1.02 (0.99–1.04)  | 0.056   |

The multivariate Cox proportional hazards model was carried out after adjustment for baseline variables of age, body mass index (BMI), duration of diabetes, presence of hypertension, estimated glomerular filtration rate (eGFR), total cholesterol, albuminuria, urinary glucose, sex, glycated hemoglobin (HbA1c) level, and the interaction terms between high glycosuria (≥5 g/day) and sex, BMI, and duration of diabetes. CI, confidence interval; HR, hazard ratio. *Values with P < 0.05 were considered to be statistically significant.

### Figure 4 | The vertical dashed line represents the commonly used cut-off value of glycated hemoglobin (HbA1c; 7%). The horizontal line at the hazard ratio of 1 denotes the equivalence of the effect of urinary glucose levels; thus, an effect function parallel to the horizontal line indicates no interaction. For the outcome, values of HbA1c where the hazard ratios are beneath this line indicate that lower levels of urinary glucose are more beneficial. The multivariable Cox proportional hazards model was adjusted for age, sex, body mass index, duration of diabetes, estimated glomerular filtration rate, total cholesterol, log-transformed urinary albumin and hypertension.
blood glucose levels and prevents glomerular hyperfiltration in a diabetic mouse model. Second, individuals with high urinary glucose levels might show lower sympathetic nerve activation. Chhabra et al. reported that glycemic conditions are regulated by a hypothalamic–sympathetic nervous system–renal axis, which controls glucose reabsorption in the proximal renal tubule. Using an animal model, the authors showed that mice with hypothalamic proopiomelanocortin deficiencies showed lower sympathetic nerve activation, resulting in reduced glucose transporter 2 expression and higher glycosuria. In human studies, mutation of the melanocortin 3 receptor – which is found on hypothalamic proopiomelanocortin neurons – resulted in improved glycemic control despite obesity and insulin resistance.

Furthermore, renal sympathetic denervation has been shown to improve blood glucose levels in patients with hypertension.

In the present study, multivariate Cox analysis including interaction terms showed that a statistically significant effect of high glycosuria was only seen in three types of patients: those with the duration of diabetes ≥10 years, men and those with low BMI (BMI <25 kg/m²). However, when all these interaction terms were analyzed in one model, low BMI was no longer statistically significant. These results suggest that patients with a longer history of diabetes, as well as male patients with high urinary glucose levels, had better renal prognoses. It might take a long time for the benefits of high glycosuria to be realized. Many studies have investigated the influence of sex on renal function, but the results have not been consistent. In the Japanese population, men have been found to be at a higher risk of CKD among patients with diabetes, whereas others have reported the opposite. In some studies from the USA, it has been shown that the prevalence of CKD is higher among men, whereas others have reported the opposite. In the present study, sex does not necessarily affect the prevalence or rate of CKD progression. Multivariate analysis in the present study failed to show a significant association between sex and renal prognosis. However, it did show that high glycosuria had beneficial effects in men, but not in women. An animal model study has also shown that male hormones exert a deleterious effect on the kidney by increasing oxidative stress, activating the renin–angiotensin system, and enhancing the fibrotic process. In patients with high glycosuria, however, the presence of male hormones might have had beneficial effects. Further studies are required to clarify the reasons for this discrepancy.

The strength of the present study was the measurement of 24-h urinary glucose excretion. In the above-mentioned previous studies, only spot urine tests were used to assess glycosuria. The process of 24-h urinary collection might be difficult for some patients, especially the elderly. However, analysis of urinary glucose by spot urine tests is susceptible to error compared with that of 24-h urinary collection. In this context, the present results should be more reliable than those of the previous studies. Of note, the proportion of patients with type 1 diabetes mellitus in the present study was 10.8%, which is higher than that in the general population. As the study facility was a regional core hospital with multiple diabetes specialists, patients with type 1 diabetes mellitus tended to be referred and retained as outpatients there. Our analyses showed that the type of diabetes was not influential in this study.

The present study had some limitations that should be acknowledged. First, it was an observational, retrospective, cohort study carried out in a single center. Even when adjustments are made, some bias effects might have remained. Furthermore, this is an exploratory study for obtaining hypotheses. Future research using different cohorts will be necessary. Second, we showed the association between 24-h urinary glucose levels and kidney function, but we did not directly measure the threshold for glucose reabsorption in the renal proximal tubules. Third, we did not analyze mutations in causative genes, such as solute carrier family 5 member 2, which is one of the most well-known genes associated with familial renal glycosuria, or proopiomelanocortin, whose deficiency causes severe obesity.

In conclusion, the present results show that high 24-h urinary glucose excretion is associated with better renal prognosis in terms of a 30% decline in eGFR compared with baseline among patients with diabetes who are not using SGLT2 inhibitors, particularly men or patients with a duration of diabetes ≥10 years. Quantification of urinary glucose by 24-h urinary collection test might, therefore, have clinical utility for identifying patients with better renal prognoses. The present results showed that high urinary glucose excretion might be associated with better renal function in a similar manner to SGLT2 inhibitors, providing better insight into the pathogenesis of diabetic kidney disease. Further studies are necessary to confirm the significance of glycosuria with respect to renal function.

ACKNOWLEDGMENTS
The authors thank all physicians and medical staff in the Department of Diabetology and Nephrology, Ogaki Municipal Hospital.

DISCLOSURE
The authors declare no conflict of interest.

REFERENCES
1. Drey N, Roderick P, Mullee M, et al. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis 2003; 42: 677–684.
2. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–1305.
3. Klein R, Klein BEK, Moss SE, et al. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 1988; 260: 2864–2871.
4. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360–367.
5. Chase HP, Jackson WE, Hoops SL, et al. Glucose control and the renal and retinal complications of insulin-dependent diabetes. JAMA 1989; 261: 1155–1160.

6. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.

7. Hung CC, Lin HY, Lee JJ, et al. Reduced renal sympathetic nerve activity contributes to elevated glycosuria and improved glucose tolerance in hypothalamic POMC deficiency. J Clin Invest 2017; 6: 1274–1285.

8. Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic advanced chronic kidney disease. Sci Rep 2016; 6: 39372.

9. Mente A, O’Donnell MJ, Dagenais G, et al. Validated and comparison of three formulae to estimate sodium and potassium excretion from a single morning fasting urine specimen. J Japanese Assoc Cerebro-Cardiovascular Dis Control 1992; 27: 39–45.

10. Jackson WP, Marine N, Vinik AI. The significance of glycosuria. Lancet 1968; 1: 933–936.

11. Abdul-Ghani M, DeFronzo R. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 2008; 14: 782–790.

12. Butterfield WJH, Keen H, Whichelow MJ. Renal glucose threshold variations with age. Br Med J 1967; 4: 505–507.

13. Yu L, Lv JC, Zhou XJ, et al. Abnormal expression and dysfunction of novel SGLT2 mutations identified in familial renal glucosuria patients. Hum Genet 2011; 129: 335–344.

14. Royston P, Sauerbrei W. A new approach to modelling non-linear relationships in clinical trials by using fractional polynomials. Stat Med 2004; 30: 2509–2525.

15. Nagata M, Ninomiya T, Doi Y, et al. Trends in prevalence of chronic kidney disease in the United States. Ann Intern Med 2016; 165: 473–481.

16. Wanner C, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323–334.

17. Vallon V, Rose M, Gerasimova M, et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 2013; 304: F156–F167.

18. Farooqi IS, Yeo GSH, Keogh JM, et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 2000; 106: 271–279.

19. Yu MK, Morgan DA, Tooko BP, et al. Reduced renal sympathetic nerve activity contributes to elevated glycosuria and improved glucose tolerance in hypothalamic-specific Pomc knockout mice. Mol Metab 2017; 6: 1274–1285.

20. Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic advanced chronic kidney disease. Sci Rep 2016; 3: 2047–2053.

21. Murphy D, McCulloch CE, Lin F, et al. Trends in prevalence of chronic kidney disease in the United States. Ann Intern Med 2016; 165: 473–481.

22. Eriksen BO, Ingebrigtsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int 2006; 69: 375–382.

23. Nagata M, Ninomiya T, Doi Y, et al. Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: the Hisayama study. Nephrol Dial Transplant 2010; 25: 2557–2564.

24. Yu MK, Katon W, Young BA. Associations between sex and incident chronic kidney disease in a prospective diabetic cohort. Nephrology 2015; 20: 451–458.

25. Yu MK, Lyles CR, Bent-Shaw LA, et al. Risk factor, age and sex differences in chronic kidney disease prevalence in a diabetic cohort: the pathways study and the pathways authors. Am J Nephrol 2012; 36: 245–251.

26. Valdivielso JM, Jacobs-Cachá C, Soler MJ. Sex hormones and their influence on chronic kidney disease. Curr Opin Nephrol Hypertens 2019; 28: 1–9.